Cargando…
Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?
Mammalian target of rapamycin (mTOR) inhibitors are currently considered an alternative immunosuppressive treatment that can prevent the nephrotoxicity, viral infections and malignancies that are associated with calcineurin inhibitor-based immunosuppressive regimens. However, the side effects of mTO...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834549/ https://www.ncbi.nlm.nih.gov/pubmed/24565231 http://dx.doi.org/10.1186/2047-1440-2-S1-S3 |